PC

Sanofi Genzyme has announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Jevtana (cabazitaxel) in England.

Jevtana, in combination with prednisone or prednisolone, can be used as a treatment option for patients suffering from metastatic hormone-relapsed prostate cancer (mHRPC).

NICE has recommended the treatment after a review.

Jevtana (cabazitaxel) is a taxane (plant-based) chemotherapy that is active in cancer cells and can resist docetaxel.

The NICE guidance (TA391) reveals that Jevtana (cabazitaxel) is a clinically-effective, as well as cost-effective treatment that helps increase the life of mHRPC patients, thereby increasing the survival rate.

Queen Elizabeth Hospital Birmingham Cancer Centre clinical oncology professor Nick James said: "I am delighted with this announcement from NICE, which represents an important milestone for men with advanced prostate cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"It means that patients will now have access to another effective treatment, which may offer extended survival to patients who have failed on other treatments."

"I am delighted with this announcement from NICE, which represents an important milestone for men with advanced prostate cancer."

Prostate cancer is currently the most common form of cancer in men, causing the deaths of nearly 10,500 men in the UK every year.

Most prostate cancers become resistant to hormone therapy with time, and thereby continue to progress in spite of proper treatment.

Jevtana is the only existing NICE approved chemotherapy option to treat advanced prostate cancer, which is not responsive to hormone therapies following initial chemotherapy (docetaxel).

National Health Service (NHS) in Wales, and Health and Social Care (HSC) Northern Ireland, are expected to adopt NICE guidance, while Jevtana (cabazitaxel) is being appraised by the Scottish Medicines Consortium (SMC) through its Health Technology Appraisal (HTA) process.


Image: Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer). Photo: courtesy of Nephron.